Resources
5 Results (showing 1 - 5)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 4/14/2021 (updated 4/5/2024)
Learning Objectives
Update milestones and due dates for Implementation and MAT Expansion annual RCORP sustainability deliverables.
Review the calendar of the upcoming sustainability webinar series
Re)Introduce Essential Elements of Sustainability
Interventions to help ensure sustainability of prevention, treatment, and recovery activities via insurance, federal, state, and foundation funding.
Posted 10/23/2020 (updated 4/3/2024)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).